CNM-ZnAg / Clene - LARVOL DELTA

Study of ZnAg Liquid Solution to Treat COVID-19 Symptomatic Participants (clinicaltrials.gov) - P2 | N=296 | Completed | Sponsor: Clene Nanomedicine | Active, not recruiting ➔ Completed

Trial completion • Infectious Disease • Novel Coronavirus Disease

Study of ZnAg Liquid Solution to Treat COVID-19 Symptomatic Participants (clinicaltrials.gov) - P2 | N=276 | Active, not recruiting | Sponsor: Clene Nanomedicine | Trial completion date: May 2022 ➔ Aug 2022

Trial completion date • Infectious Disease • Novel Coronavirus Disease

Study of ZnAg Liquid Solution to Treat COVID-19 Symptomatic Participants (clinicaltrials.gov) - P2 | N=276 | Active, not recruiting | Sponsor: Clene Nanomedicine | Not yet recruiting ➔ Active, not recruiting | Trial completion date: Aug 2021 ➔ May 2022 | Trial primary completion date: Jul 2021 ➔ May 2022

Enrollment closed • Trial completion date • Trial primary completion date • Infectious Disease • Novel Coronavirus Disease

Clene Nanomedicine Initiates Phase 2 Study of CNM-ZnAg for Patients with COVID-19 (GlobeNewswire) - "...Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company, received official ANVISA approval in Brazil to commence its multicenter, randomized, double-blind, placebo-controlled study assessing the efficacy and safety of CNM-ZnAg liquid solution in a Phase 2 clinical study...Participants in the Phase 2 study must have presented with two or more symptoms of acute COVID-19 infection within 96 hours prior to baseline visit, self-reported as moderate or severe....Enrollment in the trial is expected to be completed in mid-2021, with results now anticipated in the second half of 2021."

New P2 trial • P2 data • Trial completion date • Infectious Disease • Novel Coronavirus Disease

Study of ZnAg Liquid Solution to Treat COVID-19 Symptomatic Participants (clinicaltrials.gov) - P2; N=238; Not yet recruiting; Sponsor: Clene Nanomedicine

Clinical • New P2 trial • Infectious Disease • Novel Coronavirus Disease